Putnam Investments’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Putnam Investments’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,556	Closed	-$331K	–	1369
2016 Q2	$331K	Hold	2,556	–	–	﹤0.01%	1250
2016 Q1	$239K	Hold	2,556	–	–	﹤0.01%	1351
2015 Q4	$518K	Hold	2,556	–	–	﹤0.01%	1309
2015 Q3	$371K	Hold	2,556	–	–	﹤0.01%	1382
2015 Q2	$544K	Hold	2,556	–	–	﹤0.01%	1334
2015 Q1	$592K	Hold	2,556	–	–	﹤0.01%	1294
2014 Q4	$589K	Buy	+2,556	New	+$548K	﹤0.01%	1271

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments's BLCM Position: Q3 2016 in Review

Putnam Investments sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2016, closing a stake of 2,556 shares — an estimated $331K sold.

Putnam Investments first reported a position in BLCM in Q4 2014 and held it in 7 quarters. The position peaked at $592K in Q1 2015. 70 funds tracked by Wall St. Rank hold BLCM as of Q3 2016.

Putnam Investments reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Putnam Investments sold 2,556 Bellicum Pharmaceuticals, Inc. shares in Q3 2016, an estimated $331K.
Putnam Investments first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
Putnam Investments's Bellicum Pharmaceuticals, Inc. position peaked at $592K in Q1 2015.
70 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2016.

Based on Putnam Investments's 13F filing for Q3 2016, filed 14 Nov 2016.